{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002731","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.226883+00:00","generated_at":"2026-05-16T10:55:22.923206+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Harmony Biosciences reports ~$868M FY2025 WAKIX revenue; guides $1.0-1.04B in 2026","bullets":["Preliminary Q4 2025 WAKIX net revenue ~$243M; FY2025 ~$868M, up ~21% YoY.","2026 WAKIX net revenue guidance of $1.0-1.04B, on track for blockbuster status.","Pitolisant GR NDA submission expected 2Q 2026; PDUFA 1Q 2027; aims to extend franchise into 2040s.","Five ongoing Phase 3 reg. trials in CNS; topline data for pitolisant HD and EPX-100 in 2027.","ZYN002 program in Fragile X discontinued; 22q deletion syndrome indication no longer pursued."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002731","json":"https://secwatch.observer/filing/0001104659-26-002731.json","markdown":"https://secwatch.observer/filing/0001104659-26-002731.md","text":"https://secwatch.observer/filing/0001104659-26-002731.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000110465926002731/0001104659-26-002731-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000110465926002731/hrmy-20260112x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:55:22.923206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}